3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a serine-threonine kinase that phosphorylates and activates a range of other kinases, including protein kinase (PK)B, PKA, and certain isoforms of PKC. BX-912 is a potent, ATP-competitive inhibitor of PDK1 (IC50 = 26 nM). It less effectively inhibits a panel of related serine-threonine kinases. BX-912 has been used to evaluate the role of PDK1 in kinase activation and cell survival.
BX-912 is a selective potent 3-Phosphoinositide-dependent Kinase-1 (PDK1) inhibitor. BX-192 shows potential anticancer properties as it inibits PDK1 activity towards the signaling pathway in cancer cell growth, survival and tumor angiogenesis.
[1] feldman ri1, wu jm, polokoff ma, kochanny mj, dinter h, zhu d, biroc sl, alicke b, bryant j, yuan s, buckman bo, lentz d, ferrer m, whitlow m, adler m, finster s, chang z, arnaiz do. novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. j biol chem. 2005 may 20;280(20):19867-74. epub 2005 mar 16.